West Common Stock Total Equity vs Short Long Term Debt Total Analysis
WST Stock | USD 364.19 1.40 0.38% |
West Pharmaceutical financial indicator trend analysis is more than just analyzing West Pharmaceutical current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether West Pharmaceutical is a good investment. Please check the relationship between West Pharmaceutical Common Stock Total Equity and its Short Long Term Debt Total accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in West Pharmaceutical Services. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
Common Stock Total Equity vs Short Long Term Debt Total
Common Stock Total Equity vs Short Long Term Debt Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of West Pharmaceutical Common Stock Total Equity account and Short Long Term Debt Total. At this time, the significance of the direction appears to have weak relationship.
The correlation between West Pharmaceutical's Common Stock Total Equity and Short Long Term Debt Total is 0.3. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Short Long Term Debt Total in the same time period over historical financial statements of West Pharmaceutical Services, assuming nothing else is changed. The correlation between historical values of West Pharmaceutical's Common Stock Total Equity and Short Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of West Pharmaceutical Services are associated (or correlated) with its Short Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt Total has no effect on the direction of Common Stock Total Equity i.e., West Pharmaceutical's Common Stock Total Equity and Short Long Term Debt Total go up and down completely randomly.
Correlation Coefficient | 0.3 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Short Long Term Debt Total
Most indicators from West Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into West Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in West Pharmaceutical Services. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. At this time, West Pharmaceutical's Sales General And Administrative To Revenue is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 30.72 in 2024, whereas Enterprise Value is likely to drop slightly above 252.4 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 2.8B | 2.9B | 2.9B | 3.1B | Depreciation And Amortization | 126.1M | 120.6M | 137.3M | 144.2M |
West Pharmaceutical fundamental ratios Correlations
Click cells to compare fundamentals
West Pharmaceutical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
West Pharmaceutical fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 2.3B | 2.8B | 3.3B | 3.6B | 3.8B | 4.0B | |
Short Long Term Debt Total | 329.3M | 325.7M | 325.3M | 317.9M | 309M | 227.6M | |
Other Current Liab | 145.4M | 226.9M | 259.7M | 228.1M | 236M | 247.8M | |
Total Current Liabilities | 341.6M | 503.4M | 594.1M | 519M | 671.8M | 705.4M | |
Total Stockholder Equity | 1.6B | 1.9B | 2.3B | 2.7B | 2.9B | 3.0B | |
Property Plant And Equipment Net | 909.4M | 1.0B | 1.1B | 1.3B | 1.5B | 1.6B | |
Net Debt | (109.8M) | (289.8M) | (437.3M) | (576.4M) | (544.9M) | (517.7M) | |
Retained Earnings | 1.5B | 1.8B | 2.5B | 3.0B | 3.5B | 3.7B | |
Cash | 439.1M | 615.5M | 762.6M | 894.3M | 853.9M | 896.6M | |
Non Current Assets Total | 1.3B | 1.4B | 1.6B | 1.7B | 1.9B | 2.0B | |
Non Currrent Assets Other | 20.5M | 29M | 36.3M | 55.9M | 38.4M | 32.0M | |
Cash And Short Term Investments | 439.1M | 615.5M | 762.6M | 894.3M | 853.9M | 896.6M | |
Net Receivables | 319.3M | 385.3M | 489M | 507.4M | 512M | 537.6M | |
Liabilities And Stockholders Equity | 2.3B | 2.8B | 3.3B | 3.6B | 3.8B | 4.0B | |
Non Current Liabilities Total | 426.6M | 435.9M | 384.3M | 412.9M | 276.7M | 307.8M | |
Inventory | 235.7M | 321.3M | 378.4M | 414.8M | 434.7M | 456.4M | |
Other Current Assets | 64.6M | 51.6M | 112M | 103M | 135.8M | 142.6M | |
Other Stockholder Equity | 154.6M | 99.6M | 19.5M | (138.7M) | (517.4M) | (491.5M) | |
Total Liab | 768.2M | 939.3M | 978.4M | 931.9M | 948.5M | 995.9M | |
Total Current Assets | 1.1B | 1.4B | 1.7B | 1.9B | 1.9B | 2.0B | |
Short Term Debt | 11.9M | 12.4M | 53.5M | 18.2M | 151.7M | 159.3M | |
Intangible Assets | 29.8M | 30.5M | 23M | 18.4M | 15.1M | 14.3M | |
Accounts Payable | 156.8M | 213.1M | 232.2M | 215.4M | 242.4M | 254.5M | |
Property Plant And Equipment Gross | 909.4M | 1.0B | 2.2B | 2.4B | 2.8B | 3.0B | |
Accumulated Other Comprehensive Income | (149.6M) | (110.6M) | (159.6M) | (183M) | (143.8M) | (151.0M) | |
Other Liab | 109.2M | 117M | 112.5M | 113.2M | 130.2M | 107.9M | |
Other Assets | 43M | 52.3M | 104.4M | 104M | 93.6M | 47.0M | |
Long Term Debt | 255M | 252.9M | 208.8M | 206.7M | 72.8M | 69.2M | |
Good Will | 107.8M | 111.1M | 109.9M | 107.3M | 108.5M | 103.1M | |
Treasury Stock | (118.1M) | (167.7M) | (229.5M) | (370.9M) | (333.8M) | (317.1M) | |
Property Plant Equipment | 839.3M | 943.2M | 1.1B | 1.2B | 1.3B | 1.4B | |
Current Deferred Revenue | 27.5M | 51M | 48.7M | 57.3M | 41.7M | 38.2M | |
Net Tangible Assets | 1.4B | 1.7B | 2.1B | 2.6B | 2.9B | 3.1B | |
Retained Earnings Total Equity | 1.5B | 1.8B | 2.5B | 3.0B | 3.4B | 3.6B | |
Long Term Debt Total | 255M | 252.9M | 208.8M | 206.7M | 186.0M | 209.4M | |
Capital Surpluse | 272.7M | 267.3M | 249M | 232.2M | 267.0M | 223.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether West Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if West Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about West Pharmaceutical Services Stock. Highlighted below are key reports to facilitate an investment decision about West Pharmaceutical Services Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in West Pharmaceutical Services. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for West Stock analysis
When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stocks Directory Find actively traded stocks across global markets | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is West Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of West Pharmaceutical. If investors know West will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about West Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.16) | Dividend Share 0.78 | Earnings Share 7.57 | Revenue Per Share 39.549 | Quarterly Revenue Growth (0.03) |
The market value of West Pharmaceutical is measured differently than its book value, which is the value of West that is recorded on the company's balance sheet. Investors also form their own opinion of West Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is West Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because West Pharmaceutical's market value can be influenced by many factors that don't directly affect West Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between West Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if West Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, West Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.